NYT’s Stance on Stem Cell Research and Kennedy’s Position

The New York Times recently addressed stem cell research, featuring insights from Robert F. Kennedy Jr., the director of Health and Human Services. Kennedy, who has personally benefited from stem cell therapy for his spasmodic dysphagia, expressed a desire to eliminate obstacles to treatment for others during “The Ultimate Human Podcast with Gary Brecca” in May. He asserted, “If you want to take lab medication, you can do that and you should be able to do that.”

However, the NYT took a different approach in their Thursday article. In a piece titled “Charratan is not a reason to block unproven stem cell therapy,” they cautioned that “several methods have resulted in blindness, tumors, and other injuries.”

Over the past eight years, some discussions around stem cell therapy have been quite positive. For instance, in 2017, the NYT highlighted the advancements made by Japanese researchers in this field. Additionally, the publication critiqued former President George W. Bush for instituting bans on federal funding for stem cell research involving human embryos, stating that his actions “have stopped research and discouraged scientists.”

Moreover, feminist writer Susan Goober echoed Kennedy’s sentiments in a 2019 NYT opinion piece, arguing against those who undermine scientific research that underscores the regenerative potential of cord blood. In the same year, another article expressed hope regarding the promise of stem cells for the 1.5 million Americans dealing with type 1 diabetes.

Despite these prior endorsements, the tone of the recent article was markedly critical. It suggested that if Kennedy were to facilitate broader access to experimental therapies, it could undo years of regulatory efforts aimed at overseeing new medical advancements.While the NYT has previously reported on FDA warnings related to stem cell therapies, those warnings were notably absent from the articles related to Kennedy Jr.